2 2 Bioaivers Experience (2)
Development of Pediatric ARV Drugs – FDA Perspective Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products U.S. Food and Drug Administration.
American Conference on Pharmacometics –San Diego, CA; April 3-6 2011 Population PK modeling incorporating enzyme induction mechanism to guide the design.
IND Filing, Timelines, Paperwork and Reports September 3, 2010 Kate Marusina, PhD, MBA Pav Aujla, MS, CCRP, RAC A Translational Innovation Forum.
An agency of the European Union Paediatric regulation and information on the use medicines in children: the experience of the SmPC Advisory Group Joint.
Development of Pediatric ARV Drugs – FDA Perspective
1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.
ChEMBL – Large-Scale Open Access Data for Drug Discovery John Overington EMBL-EBI [email protected].
